A prospective, open-label, non-comparative study of ambrisentan with anti-fibrotic agent combination therapy in the treatment of diffuse systemic sclerosis
Abstract Background Systemic Sclerosis is a multifactorial autoimmune rheumatic disease characterized by inflammation, fibrosis, immune dysregulation and vascular dysfunction. Methods An open label, prospective, non-comparative study evaluating ambrisentan with an antifibrotic agent in diffuse cutan...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2018-05-01
|
| Series: | BMC Rheumatology |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s41927-018-0021-z |